PriceTargets.com logo

Keros Therapeutics - KROS Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $81.33
  • Forecasted Upside: 377.59%
  • Number of Analysts: 14
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
$17.03 As of 12/20/2024 06:31 PM ET
▲ +0.11 (0.65%)

This chart shows the closing price for KROS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Keros Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KROS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KROS

Analyst Price Target is $81.33
▲ +377.59% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for Keros Therapeutics in the last 3 months. The average price target is $81.33, with a high forecast of $111.00 and a low forecast of $44.00. The average price target represents a 377.59% upside from the last price of $17.03.

This chart shows the closing price for KROS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 14 polled investment analysts is to moderate buy stock in Keros Therapeutics. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 10 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/16/2024OppenheimerLower TargetOutperform ➝ Outperform$102.00 ➝ $63.00
12/16/2024GuggenheimDowngradeBuy ➝ Neutral
12/13/2024ScotiabankLower TargetSector Outperform ➝ Sector Outperform$77.00 ➝ $44.00
12/13/2024HC WainwrightLower TargetBuy ➝ Buy$100.00 ➝ $47.00
12/12/2024TD CowenDowngradeBuy ➝ Hold
12/12/2024BTIG ResearchDowngradeBuy ➝ Neutral
12/12/2024William BlairDowngradeOutperform ➝ Market Perform
12/11/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$88.00 ➝ $111.00
12/4/2024GuggenheimReiterated RatingBuy ➝ Buy$96.00 ➝ $102.00
11/22/2024Cantor FitzgeraldReiterated RatingOverweight
11/7/2024WedbushReiterated RatingOutperform$84.00
11/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$100.00 ➝ $100.00
11/5/2024Jefferies Financial GroupInitiated CoverageBuy
11/4/2024WedbushUpgradeStrong-Buy
10/24/2024Cantor FitzgeraldInitiated CoverageOverweight
10/16/2024ScotiabankInitiated CoverageSector Outperform$77.00
9/23/2024GuggenheimInitiated CoverageBuy$96.00
9/12/2024Bank of AmericaLower TargetBuy ➝ Buy$81.00 ➝ $76.00
6/25/2024OppenheimerInitiated CoverageOutperform$102.00
6/18/2024Truist FinancialReiterated RatingBuy ➝ Buy$100.00 ➝ $100.00
6/18/2024HC WainwrightReiterated RatingBuy ➝ Buy$100.00 ➝ $100.00
5/9/2024HC WainwrightReiterated RatingBuy ➝ Buy$100.00
3/27/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$105.00
3/13/2024Truist FinancialReiterated RatingBuy ➝ Buy$100.00
3/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$100.00
2/29/2024WedbushReiterated RatingOutperform$86.00
2/21/2024William BlairReiterated RatingOutperform
1/3/2024WedbushReiterated RatingOutperform$86.00
12/8/2023Wells Fargo & CompanyInitiated CoverageOverweight$60.00
11/13/2023WedbushReiterated RatingOutperform ➝ Outperform$86.00
8/31/2023WedbushReiterated RatingOutperform ➝ Outperform$86.00
8/8/2023WedbushReiterated RatingOutperform ➝ Outperform$86.00
8/7/2023HC WainwrightReiterated RatingBuy ➝ Buy$100.00
7/31/2023WedbushInitiated CoverageOutperform$86.00
7/26/2023Bank of AmericaInitiated CoverageBuy$65.00
5/5/2023Piper SandlerLower Target$120.00 ➝ $110.00
3/6/2023HC WainwrightReiterated RatingBuy$100.00
2/14/2023CowenInitiated CoverageOutperform
2/14/2023CowenInitiated CoverageOutperform
12/13/2022BTIG ResearchBoost TargetBuy$95.00 ➝ $105.00
10/18/2022Truist FinancialInitiated CoverageBuy$100.00
9/13/2022BTIG ResearchBoost Target$80.00 ➝ $95.00
7/26/2022BTIG ResearchInitiated CoverageBuy$80.00
6/10/2022HC WainwrightReiterated RatingBuy$100.00
5/18/2022Piper SandlerBoost TargetNA$90.00 ➝ $120.00
3/10/2022HC WainwrightReiterated RatingBuy$100.00
8/9/2021HC WainwrightReiterated RatingBuy$100.00
8/6/2021Piper SandlerLower TargetOverweight$95.00 ➝ $90.00
6/27/2021Leerink PartnersReiterated RatingBuy
6/23/2021Jefferies Financial GroupReiterated RatingBuy$70.00
12/8/2020HC WainwrightBoost TargetBuy$50.00 ➝ $100.00
12/8/2020Leerink PartnersBoost TargetOutperform$42.00 ➝ $80.00
12/8/2020Piper SandlerBoost TargetOverweight$75.00 ➝ $95.00
11/18/2020Piper SandlerBoost TargetOverweight$55.00 ➝ $75.00
9/13/2020Piper SandlerBoost TargetOverweight$45.00 ➝ $55.00
5/27/2020Piper SandlerBoost TargetOverweight$35.00 ➝ $45.00
5/4/2020HC WainwrightInitiated CoverageBuy$50.00
5/4/2020Leerink PartnersInitiated CoverageOutperform$42.00
5/4/2020Jefferies Financial GroupInitiated CoverageBuy$37.00
5/3/2020Piper SandlerInitiated CoverageOverweight$35.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.56 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 8 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 10 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 12 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 12 very positive mentions
  • 13 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 23 very positive mentions
  • 27 positive mentions
  • 11 negative mentions
  • 1 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 23 very positive mentions
  • 27 positive mentions
  • 11 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Keros Therapeutics logo
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Read More

Today's Range

Now: $17.03
Low: $16.62
High: $17.64

50 Day Range

MA: $54.97
Low: $16.92
High: $70.00

52 Week Range

Now: $17.03
Low: $15.67
High: $73.00

Volume

1,468,811 shs

Average Volume

487,363 shs

Market Capitalization

$689.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2

Frequently Asked Questions

What sell-side analysts currently cover shares of Keros Therapeutics?

The following Wall Street analysts have issued stock ratings on Keros Therapeutics in the last twelve months: Bank of America Co., BTIG Research, Cantor Fitzgerald, Guggenheim, HC Wainwright, Jefferies Financial Group Inc., Oppenheimer Holdings Inc., Piper Sandler, Scotiabank, TD Cowen, Truist Financial Co., Wedbush, Wells Fargo & Company, and William Blair.
View the latest analyst ratings for KROS.

What is the current price target for Keros Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Keros Therapeutics in the last year. Their average twelve-month price target is $81.33, suggesting a possible upside of 377.6%. Wells Fargo & Company has the highest price target set, predicting KROS will reach $111.00 in the next twelve months. Scotiabank has the lowest price target set, forecasting a price of $44.00 for Keros Therapeutics in the next year.
View the latest price targets for KROS.

What is the current consensus analyst rating for Keros Therapeutics?

Keros Therapeutics currently has 4 hold ratings and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for KROS.

What other companies compete with Keros Therapeutics?

Other companies that are similar to Keros Therapeutics include Merus, ACADIA Pharmaceuticals, Twist Bioscience, Vericel and MorphoSys. Learn More about companies similar to Keros Therapeutics.

How do I contact Keros Therapeutics' investor relations team?

Keros Therapeutics' physical mailing address is 99 HAYDEN AVENUE SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER, LEXINGTON MA, 02421. The company's listed phone number is 617-314-6297 and its investor relations email address is [email protected]. The official website for Keros Therapeutics is www.kerostx.com. Learn More about contacing Keros Therapeutics investor relations.